Topic:

M&A

Latest Headlines

Latest Headlines

Ulthera device clears FDA for décolleté on heels of Merz acquisition plans

Merz already committed to buying Ulthera for up to $600 million in cash and milestones. Now it will get another FDA-cleared indication as part of the bargain. The company's system has cleared the FDA to improve the lines and wrinkles of the décolleté.

Ackman puts forth his slate of new Allergan directors

Things are getting real in leading shareholder Pershing Square Capital Management's fight to overturn Allergan's board and install a new slate of directors more amenable to Valeant's $53 billion buyout offer. Monday, Pershing Square--run by Valeant's takeover partner, Bill Ackman--announced the proposed slate of 6 new directors it hopes will help it seal the deal.

Covidien picks integration chief for Medtronic merger

As Covidien strides into a merger with Medtronic, the company last week announced the appointment of Bill Burke as CFO for Covidien Europe.

Nicox's $120M Aciex deal gives CRO Ora a bigger partner

Ophthalmic CRO Ora is inheriting a relationship with drugmaker Nicox after the French outfit agreed to buy Aciex Therapeutics, a Boston-based biotech at work on eye treatments.

AMRI eyes a big year after completing another buyout

Contract developer AMRI has closed its $110 million acquisition of drug manufacturer Oso Biopharmaceuticals, its second deal this year and one the company believes will help pad its annual revenue.

Quintiles extends its commercial capabilities with Encore buyout

Quintiles has wrapped up its acquisition of healthcare analytics provider Encore, part of the CRO's push to grow its post-market services.

AbbVie chief quietly touts his Shire deal to shareholders, signaling a new bid

After three failed bids for Ireland's Shire, AbbVie CEO Richard Gonzalez may be considering upping his bid. But first, he's making his case to major to Shire shareholders, urging them to put the heat on the company to come to the bargaining table.

J&J cuts 400 medical device jobs, as Covidien hires more than 100

Hiring ahead of and cutting after mergers is always tricky, but organizational change marches on. Post-merger Johnson & Johnson and pre-merger Covidien are both forging ahead, with cuts in J&J's DePuy Synthes and hiring for Covidien.

Exec talks on Covidien's fit with Medtronic

The president of Covidien's $1.6 billion vascular product group said that the impending merger with Medtronic was necessary from her perspective because being "a vascular player without cardiovascular, I think long term that would have been a real issue.

Bayer likes all the brands it got from Merck, Coppertone and Dr. Scholl's included

Should Bayer sell some of the consumer brands it's buying from Merck in a $14 billion deal? Analysts say a few of them--Coppertone sun products, for instance--don't quite fit with Bayer's product lineup. Buyers appear to be knocking. But Bayer says it will keep those brands, thank you very much.